Abbott and Medica Corporation announced today that they have entered into an exclusive agreement for the world wide commercialization of the CELL-DYN® EasyCellT™ Digital Cell Morphology System for use in hospitals and clinical laboratories. This system automates the location of white blood cells on a stained blood film and pre-classifies them, improving the efficiency of the lab.
Under terms of the agreement, Medica will manufacture the Digital Cell Morphology System, and Abbott will have exclusive distribution rights under the CELL-DYN EasyCell brand name. Abbott will be responsible for the system’s sales, marketing and customer support.
“This agreement with Medica complements the current CELL-DYN instrument portfolio and demonstrates Abbott’s continuing commitment to provide innovative products that increase the laboratory’s productivity and efficiency,” said John Mooradian, divisional vice president and general manager, Abbott Hematology.
“We are pleased to be commercializing our new EasyCell™ hematology analyzer through Abbott. We believe the combination of sophisticated pattern recognition technology with a novel mechanical platform makes EasyCell a cost-effective, logical addition to hematology laboratories worldwide,” said Robert W Hagopian, president, Medica Corporation.
Medica develops, manufactures and distributes a line of easy-to-use and easy -to-service in-vitro diagnostic products for hospitals and clinical laboratories for electrolytes, blood gas, hematology and clinical chemistry. Product design has made the company a leader in bringing both cost efficiency and high performance to laboratories found in both developed and emerging markets. Medica’s blood analysis products are sold in over 120 countries.
Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs 65,000 people and markets its products in more than 130 countries.